Pandemic Darlings The pandemic economy, in original documents
Home Source documents Statement to Senate, No. 526 - Senate Commerce Committee, with committee amendments (New Jersey, 2020)

Statement to Senate, No. 526 - Senate Commerce Committee, with committee amendments (New Jersey, 2020)

Summary

A Senate Commerce Committee Statement to Senate for Senate Bill No. 526, with committee amendments, State of New Jersey, dated January 27, 2020, reporting the bill favorably and with committee amendments. The statement says the bill makes findings concerning the rising cost of insulin and requires listed health benefits plans to cover insulin for the treatment of diabetes. It says insulin purchases would not be subject to any deductible and that the copayment or coinsurance for an insulin prescription would be limited to $50 per 30 day supply. It also says insulin manufacturers would submit an annual report to the Commissioner of Banking and Insurance.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Statement to Senate, No. 526 - Senate Commerce Committee, with committee amendments (New Jersey, 2020).” Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/2020-01-27-scm-s526-s1-bd7834d1ec/, SHA-256 aaa1917465b2b6a5f71f471cb7b159be22aa06ddf5be1d9a66a84cf6409335f1.

Full text

     SENATE COMMERCE COMMITTEE

                    STATEMENT TO

                   SENATE, No. 526
                   with committee amendments



 STATE OF NEW JERSEY
                    DATED: JANUARY 27, 2020

   The Senate Commerce Committee reports favorably and with
committee amendments Senate Bill No. 526.
    This bill makes certain findings and declarations concerning the
rising cost of insulin and requires health benefits plans issued
pursuant to the New Jersey Individual Health Coverage and Small
Employer Health Benefits Programs, the State Health Benefits
Program, and the School Employees’ Health Benefits Program, to
provide coverage for insulin for the treatment of diabetes. The bill
further requires health insurers (health, hospital and medical service
corporations, commercial individual and group health insurers, and
health maintenance organizations) and health benefits plans issued
pursuant to the New Jersey Individual Health Coverage and Small
Employer Health Benefits Programs, the State Health Benefits
Program, and the School Employees’ Health Benefits Program to
provide coverage for the purchase of insulin that is not subject to any
deductible and to limit the copayment or coinsurance that may be
required for an insulin prescription to $50 per 30 day supply of
insulin.
    The bill also requires insulin manufacturers to submit an annual
report to the Commissioner of Banking and Insurance containing
certain information concerning the manufacture, pricing, and sales of
insulin products.
    This bill was pre-filed for introduction in the 2020-2021 session
pending technical review. As reported, the bill includes the changes
required by technical review, which has been performed.

COMMITTEE AMENDMENTS:
    The committee amended the bill to:
    (1) provide that the purchase of insulin shall not be subject to any
deductible and require health insurers to limit the copayment or
coinsurance that may be required for an insulin prescription to $50 per
30 day supply of insulin;
    (2) add findings and declarations concerning the rising cost of
insulin prices;
    (3) require insulin manufacturers to submit an annual report to the
Commissioner of Banking and Insurance containing certain
                                2

information concerning the manufacture, pricing, and sales of insulin
products; and
    (4) make certain technical changes.

File and source

File
2020-01-27_SCM_S526_S1.pdf
Size
115,052 bytes
SHA-256
aaa1917465b2b6a5f71f471cb7b159be22aa06ddf5be1d9a66a84cf6409335f1
Our copy
2020-01-27_SCM_S526_S1.pdf
Original
No public link identified.
Back to top